1.	Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer Phase: Phase IV Type: Supportive care, Treatment Status: Completed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: D5392C00050, SABRE, NCT00082277
2.	Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors Phase: Phase IV Type: Diagnostic, Supportive care, Treatment Status: Closed Age: 40 to 65 Sponsor: Other Protocol IDs: 2004/949, NCT00111241
3.	Arimidex Observational: Reason for and Effect of Change From Tamoxifen Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D5392NL0002, ARREST, NCT00246961
4.	Arthralgia During Anastrozole Therapy for Breast Cancer Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D5392L00013, 2005-00-5441-19 EUDRACT number, NCT00323479
5.	Liver Safety Under Upfront Arimidex vs Tamoxifen Phase: Phase IV Type: Treatment Status: Completed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: D5392L00023, NCT00537771
6.	Phase II/III Randomized Study of Anastrozole With or Without Trastuzumab (Herceptin) in Postmenopausal Women With Hormone-Receptor Positive HER2-Overexpressing Metastatic Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ROCHE-BO16216, CWRU-030118, GENENTECH-H2223g, ROCHE-1100, ROCHE-B016216F, NCT00022672
7.	Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: Postmenopausal Sponsor: NCI, Other Protocol IDs: CDR0000456382, ACOSOG-Z1031, CALGB-ACOSOG-Z1031, SDC1, NCT00265759
8.	Phase III Randomized, Double-Blind Study of Anastrozole vs Tamoxifen as First-Line Therapy in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 06/98) Phase: Phase III Type: Treatment Status: Closed Age: any age Sponsor: Pharmaceutical / Industry Protocol IDs: ZENECA-1033IL/0030, NCI-V96-1049
9.	Phase III Randomized Study of ICI 182780 (Faslodex) versus Anastrozole in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 11/1999) Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: RPCI-DS-97-29, ZENECA-9238IL/0021, NCI-G98-1412
10.	Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: CDR0000269549, FRE-FNCLCC-PACS-03/003, EU-20237, NCT00053911
11.	Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000334899, SWOG-S0221, S0221, NCT00070564
12.	Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Phase: Phase III Type: Treatment Status: Closed Age: 40 to 70 Sponsor: Other Protocol IDs: ISRCTN37546358, EU-20226, BIG-5-02, IBCSG-31-03-DCIS, ISRCTN31488319, CRUK-IBIS-II-DCIS, NCT00072462
13.	S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: Postmenopausal Sponsor: NCI, Other Protocol IDs: CDR0000349337, U10CA032102, S0226, CAN-NCIC-MAC7, SWOG-S0226, NCT00075764
14.	Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer Phase: Phase III Type: Prevention Status: Closed Age: 40 to 70 Sponsor: Other Protocol IDs: ISRCTN31488319, EU-20227, EUDRACT-2004-003991-12, CRUK-IBIS-IIB, IBCSG-31-03-PREV, NCT00078832
15.	Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: Postmenopausal Sponsor: Other Protocol IDs: ALCC 04.02, NCT00122356
16.	Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A5991048, NCT00143390
17.	Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Other Protocol IDs: CDR0000448616, ICR-CTSU-SOFEA, EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422
18.	Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: No age specified Sponsor: Pharmaceutical / Industry Protocol IDs: CFEM345D2411, 2005-004263-35, EUDRACT number 2005-004263-35, NCT00248170
19.	Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy Phase: Phase III Type: Treatment Status: Completed Age: No age specified Sponsor: Pharmaceutical / Industry Protocol IDs: D6997L00002, 9238SW/0001, FACT, NCT00256698
20.	Secondary Adjuvant Long Term Study With Arimidex Phase: Phase III Type: Treatment Status: Closed Age: 80 and under Sponsor: Pharmaceutical / Industry Protocol IDs: D5392L00016, ABCSG 16, 1033AU/0003, SALSA, NCT00295620
21.	Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 19 to 59 Sponsor: Other Protocol IDs: ABCSG-12, CZOL 446 1B 01, Zol-A-01, NCT00295646
22.	Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Phase: Phase III Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Closed Age: 18 to 75 Sponsor: NCI Protocol IDs: NCI-2009-00707, PACCT-1, CDR0000472066, ECOG-PACCT-1, U10CA021115, NCT00310180
23.	Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D5392NL003, EUDRAct No: 2005-006167-31, NCT00301457
24.	Faslodex Advanced Breast Cancer Local Chinese Study Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D6997L00004, NCT00327769
25.	Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment Phase: Phase III Type: Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D539BC00001, NCT00605267